A share price of MoonLake Immunotherapeutics [MLTX] is currently trading at $53.78, down -0.70%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MLTX shares have gain 2.20% over the last week, with a monthly amount drifted -0.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on July 28, 2025, when Rothschild & Co Redburn initiated its Neutral rating and assigned the stock a price target of $65. Previously, Wolfe Research upgraded its rating to Outperform on May 19, 2025, and kept the price target unchanged to $61. On March 18, 2025, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $67 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $82 on January 17, 2025. Wolfe Research downgraded its rating to Peer Perform for this stock on August 26, 2024. In a note dated June 25, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $104 on this stock.
MoonLake Immunotherapeutics experienced fluctuations in its stock price throughout the past year between $31.42 and $61.87. Currently, Wall Street analysts expect the stock to reach $76.25 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $53.78 at the most recent close of the market. An investor can expect a potential return of 41.78% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at -10.82% with Operating Profit Margin at -1972.27%, Pretax Profit Margin comes in at -1754.92%, and Net Profit Margin reading is -1732.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.42 and Total Capital is -0.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for MoonLake Immunotherapeutics [NASDAQ:MLTX] is 16.65. As well, the Quick Ratio is 16.65, while the Cash Ratio is 11.21.
Transactions by insiders
Recent insider trading involved Moukheibir Catherine, Director, that happened on Jul 03 ’25 when 23500.0 shares were sold. Director, Moukheibir Catherine completed a deal on Jul 03 ’25 to buy 23500.0 shares. Meanwhile, Director BVF PARTNERS L P/IL sold 2.0 million shares on Oct 04 ’24.
